MCM
ENZY

Matterhorn Capital Management’s Enzymotec Ltd ENZY Stock Holding History

Matterhorn Capital Management’s Portfolio ENZY Stock Details ENZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-257,759
Closed -$3.5M – 58
2014
Q2 		$3.5M Buy
257,759
+134,053
+108% +$2.25M 1.55% 25
2014
Q1 		$2.71M Buy
+123,706
New +$3.28M 1.25% 49

Other funds holding ENZY

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MACM
March Altus Capital Management Greenwich, Connecticut $16M AUM 18.92% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Matterhorn Capital Management's ENZY Position: Q3 2014 in Review

Matterhorn Capital Management sold out of Enzymotec Ltd (ENZY) in Q3 2014, closing a stake of 257,759 shares — an estimated $3.5M sold.

Matterhorn Capital Management first reported a position in ENZY in Q1 2014 and held it in 2 quarters. The position peaked at $3.5M in Q2 2014. 22 funds tracked by Wall St. Rank hold ENZY as of Q3 2014.

  • Matterhorn Capital Management reported no remaining Enzymotec Ltd position as of Q3 2014 after selling out during the quarter.
  • Matterhorn Capital Management sold 257,759 Enzymotec Ltd shares in Q3 2014, an estimated $3.5M.
  • Matterhorn Capital Management first reported a position in Enzymotec Ltd in Q1 2014 and held it in 2 quarters.
  • Matterhorn Capital Management's Enzymotec Ltd position peaked at $3.5M in Q2 2014.
  • 22 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q3 2014.

Based on Matterhorn Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.